CSIMarket
 
Dexcom Inc   (DXCM)
Other Ticker:  
 
 
Price: $134.3000 $0.44 0.329%
Day's High: $135.99 Week Perf: -1.35 %
Day's Low: $ 133.58 30 Day Perf: 2.94 %
Volume (M): 2,117 52 Wk High: $ 142.00
Volume (M$): $ 284,246 52 Wk Avg: $116.25
Open: $134.36 52 Wk Low: $74.75



 Market Capitalization (Millions $) 55,941
 Shares Outstanding (Millions) 417
 Employees 6,300
 Revenues (TTM) (Millions $) 3,622
 Net Income (TTM) (Millions $) 542
 Cash Flow (TTM) (Millions $) -76
 Capital Exp. (TTM) (Millions $) 237

Dexcom Inc
Dexcom Inc. is a medical device company that specializes in developing and manufacturing continuous glucose monitoring (CGM) systems for people with diabetes. The company was founded in 1999 by Scott Krasner and John Wilson.

The company's CGM devices use a sensor that is inserted under the skin to measure the glucose level in the interstitial fluid, which is the fluid that surrounds the cells in the body. The device is connected to a transmitter that wirelessly sends the glucose readings to a receiver, which displays the glucose values in real-time. Dexcom's CGM systems enable people with diabetes to continuously monitor their glucose levels, allowing them to track trends and make better decisions about insulin dosing, diet, and exercise.

Dexcom's CGM systems have been clinically proven to be highly accurate, with a mean absolute difference (MAD) of less than 10% compared to laboratory reference values. The company has also received numerous regulatory approvals and clearances, including FDA approval for the Dexcom G6 system in 2018.

The company has a range of CGM devices, including the Dexcom G6, Dexcom G5, and Dexcom G4 Platinum. The Dexcom G6 is the company's latest CGM system, which features a smaller sensor, longer wear time, and no need for calibration. The device is also compatible with mobile apps, allowing users to receive real-time glucose readings on their smartphones.

Dexcom has a strong focus on research and development, investing heavily in new technologies and features. The company has partnerships with leading diabetes advocacy organizations and universities, working closely with healthcare professionals and patients to develop new products and services to improve diabetes management.

Dexcom has a global presence, with offices and operations in the United States, Europe, Asia, and Australia. The company has a strong reputation in the diabetes community, with a dedicated customer support team and an active online community. Dexcom's vision is to help people with diabetes live their lives to the fullest, using technology to make diabetes management easier, more accurate, and more convenient.


   Company Address: 6340 Sequence Drive San Diego 92121 CA
   Company Phone Number: 200-0200   Stock Exchange / Ticker: NASDAQ DXCM
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Dexcom Empowers Diabetes Management with AID and CGM: New Data Reinforces Their Leadership and Impact on Type 2 Diabetes

Published Tue, Mar 5 2024 8:00 AM UTC

Dexcom Demonstrates Leadership in AID and CGM's Impact on Type 2 Diabetes Management: New Data Presented at ATTDEDINBURGH, Scotland - DexCom, Inc. (NASDAQ: DXCM), the leading provider of real-time continuous glucose monitoring (CGM) for individuals with diabetes, recently revealed compelling new clinical evidence that reinforces the value of using Dexcom CGM in automated ins...

Dexcom Inc

Dexcom Inc. Achieves Remarkable Surge in Revenue, Reporting 26.938% Increase in Q4 2023 Sales

Dexcom Inc, a medical equipment and supplies company, has shown impressive growth in its financial performance in the December 31, 2023 report. The company reported a notable increase in net profit per share, soaring by 608.07% year on year to $0.60 per share. Additionally, revenue increased by 26.938% to $1.03 billion. This significant growth in earnings per share more than doubled by 107.37% from $0.29 per share, and revenue surged by 6.21% from $974.30 million.
Furthermore, Dexcom Inc reported a substantial increase in net earnings, reaching $256.300 million in the October to December 31, 2023 span, which represented a growth of 179.19% from the previous year. The company also highlighted an improvement in profit margins, with a net margin of 24.77% and an operating margin of 20.96% during the same period.

Dexcom Inc

Dexcom Inc Defies Market Challenges, Achieves Impressive Results with Soaring Revenue and Profits in Q3 2023 Earnings Season

Dexcom Inc Shines Amidst Challenging Market Conditions, Showcasing Impressive Results
In the face of a challenging economic climate, Dexcom Inc has managed to defy expectations and deliver outstanding financial results in its most recent fiscal period. With revenue soaring by an impressive 26.598%, reaching a staggering $974.30 million, and profits up by 20.83% at $0.29 per share, the company's performance has left many in awe. This achievement is particularly remarkable when compared to the downturn experienced by the rest of the Medical Equipment & Supplies industries, which saw a decline of -0.33% in business.
The influx of income has been significant, with a 3.57% increase from the previous quarter, rising from $0.28 per share. Furthermore, revenue has advanced by 11.821% from $871.30 million, showcasing Dexcom Inc's ability to consistently improve its financial standing. It is important to note that net earnings saw a notable increase of 19.27%, totaling $120.700 million in the most recent fiscal period, compared to $101.200 million reported in the same period of the previous year.

Dexcom Inc

Dexcom Inc's Profits Skyrocket by 133.33%, Revealing a Resilient Performance Despite Industry-wide Decline - Reports Q2 2023

As a stock market journalist, it is my duty to interpret financial results and provide insights to investors. Looking at the Jun 30, 2023 report of Dexcom Inc, it is evident that the company has shown a commendable improvement in its performance.
One of the most notable aspects of Dexcom Inc's financial results is the significant increase in net profit per share. The net profit per share more than doubled by 133.33% year on year to reach $0.28 per share. This indicates a strong improvement in profitability and efficiency.






 

Dexcom Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Dexcom Inc does not provide revenue guidance.

Earnings Outlook
Dexcom Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com